Clover Corporation Limited · ASX:CLV
Clover — Shareholder Meeting (November 2015)
18 slides from Clover's shareholder meeting presentation, Nov 27, 2015
Slide 1: 2015 Annual General Meeting ASX Announcement
For personal use only Clover Corporation Limited ABN 85 003 622 866 ASX ANNOUNCEMENT 27 November 2015 The Manager Company Announcements Office ASX Limited 20 Bridge Street SYDNEY NSW 2000 2015 ANNUAL GENERAL MEETING Enclosed is the transcript of the Chairman’s Address and a copy of the presentation
Slide 2: Chairman's Address 2015
For personal use only Clover Corporation Limited Chairman’s Address 2015 It goes without saying that the 2015 financial year result was disappointing. Despite a sales increase of 10% the business continued to experience margin pressure during the year, due both to a change in the sales mix as custom
Slide 3: Chairman's Address 2015 (continued)
For personal use only 5) Despite the market dynamics for infant formula in China we see this growth continuing as the government relaxes its one child policy; 6) The company is developing market opportunities in Europe and the Americas. Peter is leaving tomorrow for Europe for two weeks to meet exis
Slide 4: Outlook
For personal use only OUTLOOK - continued growth in the infant formula market; - diversification in both product mix and customers. Already good work has been done in this area which will result in new sales opportunities during 2016 and 2017; - commissioning of the spray dryer in New Zealand leadin
Slide 5: Managing Director Report
For personal use only Managing Director Report 2015 AGM 27 November 2015
Slide 6: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision: To optimise the health and development of adults, infants and children. Mission: To deliver science based bioactives which provide health benefits to adults, infants, children and to the medical food markets.
Slide 7: FY 2015 Results
For personal use only FY 2015 Results AUD million 4E Reported 4E Reported •10% year on year revenue 31 July 2015 31 July 2014 growth Revenue $29.9 $27.2 •Recovery of traditional Profit before nil $1.2 markets and customers and tax encouraging growth in sales to EBITDA $0.6 $1.6 new customers EBIT ni
Slide 8: Balance Sheet July 2015
For personal use only Balance Sheet 31 July 2015 AUD million Reported Reported Movement 31 July 2015 31 July 2014 Cash $9.6 $8.0 1.6 Ç •Cash balance strong ($9.6m) Trade $5.5 $6.9 1.4 È Receivables •A key focus has Inventories $14.2 $16.5 2.3 È reduced Inventories Total Current $29.5 $32.9 3.4 È Ass
Slide 9: Delivery systems based on a variety of nutritional bioactives
Delivery systems based on a variety of For personal use only nutritional bioactives • Product portfolio includes Sales Revenue based on encapsulated powders Diversified Bioactives in FY2015 containing marine oil, algal oils, other specialty oils and important micronutrients • Encapsulation technolog
Slide 10: Sales by geography/product
For personal use only Sales by geography/product FY 2015 Geographic Reach • Continued strong presence through Oceania and Asia Australia / New Zealand 40% Asia 44% • Investment in New Zealand Europe 8% Dairy and Infant formula is providing new opportunities Americas 8% • Encapsulation technology str
Slide 11: Growth by new customers F'15 to F'16
For personal use only Growth by new customers F’15 to F’16 • A focus on new customers has provided sales growth Customer Revenue Sources in the first quarter year on 100% year 95% 90% • This provides an improved 85% risk profile and increased 80% overall revenue 75% Q1 FY'15 Q1 FY'16 • The AUD:USD e
Slide 12: Growth Platforms
Growth Platforms For personal use only 3 Core Areas of Focus… Focus on infant formula customers and market New Development Product, of Medical Process and Foods Market Program Development
Slide 13: Growth Platform: Focus on infant formula customers and market
Focus on For personal use only Growth Platform 1 infant formula customers •Continued focus on the infant formula market and market – The Chinese market is recovering and we have seen a realignment of distribution channels into China – New accounts have achieved Chinese import licences in Australia a
Slide 14: Growth Platform: New Products, Process and Market Development
New Products, Process and For personal use only Growth Platform 2 Market Development • Developing new markets – Investment in the NZ spray dryer is complete with products in trial with new and existing customers. We expect this to deliver revenue in FY’16. – This facility opens opportunities to acce
Slide 15: Growth Platform: Develop medical food program
For personal use only Growth Platform 3 •Develop medical food program –We have a product pipeline aimed at improving the health of preterm infants as well as a focus on other medical food applications • Premneo Update: –The Major phase 3 clinical trial for respiratory health has recruited 1273 babie
Slide 16: Operational Platforms
For personal use only Operational Platforms Supply • Qualification of alternate Chain quality suppliers security and integration Clover and Employee Nu-Mega development brand and development engagement • Leveraging our • Great people serving Nu-Mega brand our customers
Slide 17: FY2016 Outlook & Priorities
For personal use only FY2016 Outlook & Priorities •Leverage the two child policy in China, grow sales in the region •Develop new product applications in collaboration with customers •Organic growth with emphasis on Oceania, Asia and Europe •Diversify product portfolio and attract new customers via N
Slide 18: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s